目前的血液學(xué)惡性腫瘤報(bào)告提供了國際專家對(duì)該領(lǐng)域最重要進(jìn)展的深入評(píng)論文章。通過發(fā)表清晰、有見地、平衡的評(píng)論，強(qiáng)調(diào)最近發(fā)表的重要論文，該雜志闡明了當(dāng)前和新出現(xiàn)的診斷、治療、管理和預(yù)防血液惡性腫瘤相關(guān)疾病的方法。本雜志旨在提供國際專家清晰、有見地、平衡的貢獻(xiàn)，這些專家回顧了最近發(fā)表的與血液學(xué)惡性腫瘤的診斷、治療、管理和預(yù)防有關(guān)的最重要的臨床發(fā)現(xiàn)。我們通過任命國際權(quán)威機(jī)構(gòu)擔(dān)任關(guān)鍵學(xué)科領(lǐng)域（如白血病、淋巴瘤、骨髓瘤、T細(xì)胞和其他淋巴增生性惡性腫瘤）的部門編輯來實(shí)現(xiàn)這一目標(biāo)。章節(jié)編輯依次選擇主要專家撰寫綜合性評(píng)論文章的主題，強(qiáng)調(diào)新的發(fā)展和最近出版的重要論文，并以注釋參考列表突出。一個(gè)國際編輯委員會(huì)審查年度目錄，向其國家/地區(qū)推薦特別感興趣的文章，并確保主題是最新的，包括新的研究。還提供了該領(lǐng)域知名人士的評(píng)論。

Current Hematologic Malignancy Reports provides in-depth review articles contributed by international experts on the most significant developments in the field. By presenting clear, insightful, balanced reviews that emphasize recently published papers of major importance, the journal elucidates current and emerging approaches to the diagnosis, treatment, management, and prevention of conditions associated with hematologic malignancy.This journal intends to provide clear, insightful, balanced contributions by international experts that review the most important, recently published clinical findings related to the diagnosis, treatment, management, and prevention of hematologic malignancy. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as leukemia, lymphoma, myeloma, and T-cell and other lymphoproliferative malignancies. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. An international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research. Commentaries from well-known figures in the field are also provided.